Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Method of regulating cell metabolism or physiology
Reexamination Certificate
2003-06-11
2008-10-21
Allen, Marianne P (Department: 1647)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Method of regulating cell metabolism or physiology
C435S325000, C530S350000, C530S397000, C530S399000
Reexamination Certificate
active
07439063
ABSTRACT:
The present invention provides a method of providing acute neuroprotection by inducing the erythropoietin (EPO) signaling pathway in neuronal cells close to or subsequent to the time of excitatory insult; and inducing an insulin-like growth factor (IGF) signaling pathway in the neuronal cells close to or subsequent to the time of excitatory insult, thereby producing a synergistic acute neuroprotective effect in the neuronal cells. The invention also provides a method of preventing or reducing the severity of a neurologic condition in a subject by administering to the subject EPO or an active fragment or analog thereof at a dose of at most 2000 U/kg; and administering to the subject an IGF or an active fragment or analog thereof, thereby providing neuroprotection and preventing or reducing the severity of the neurologic condition. Such a method can be used to prevent or reduce the severity of, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, amyotrophic lateral sclerosis, multiple sclerosis, a movement disorder, HIV-associated dementia, HIV-associated neuropathy, neuropathic pain, migraine, glaucoma, drug addiction, drug withdrawal, drug dependency, depression or anxiety.
REFERENCES:
patent: 4745179 (1988-05-01), Ueda et al.
patent: 4876242 (1989-10-01), Applebaum et al.
patent: 5164370 (1992-11-01), Ballard et al.
patent: 5470828 (1995-11-01), Ballard et al.
patent: 5578324 (1996-11-01), Dohi et al.
patent: 5622932 (1997-04-01), DiMarchi et al.
patent: 5624898 (1997-04-01), Frey, II
patent: 5652214 (1997-07-01), Lewis et al.
patent: 5750376 (1998-05-01), Weiss et al.
patent: 5767078 (1998-06-01), Johnson et al.
patent: 5837675 (1998-11-01), Brox
patent: 5885962 (1999-03-01), Lu
patent: 6153407 (2000-11-01), Sytkowski et al.
patent: 6165783 (2000-12-01), Weiss et al.
patent: 6180603 (2001-01-01), Frey, II
patent: 6201072 (2001-03-01), Rathi et al.
patent: 6251865 (2001-06-01), Clark et al.
patent: 6313093 (2001-11-01), Frey, II
patent: 6342478 (2002-01-01), Frey, II
patent: 6407061 (2002-06-01), Frey, II
patent: 6464959 (2002-10-01), Cutie et al.
patent: 6531121 (2003-03-01), Brines et al.
patent: 6908902 (2005-06-01), Plata-Salaman et al.
patent: 7041794 (2006-05-01), Escary
patent: 19857609 (2000-06-01), None
Loddick et al. Neuroprotective effects of insulin-like growth factor (IGF)-I and IGF-binding protein ligand inhibitors:Novel strategies for the treatment of stroke. Pharmacology of cerebral ischemia 1998, International symposium on pharmacology of cerebral ischemia, pp. 349-354 (7th Markburg Jul. 27-29, 1998).
Ikegaya et al., Regionally selective neurotoxicity of NMDA and colchicine is independent of hippocampal neural circuity. Neuroscience, vol. 113, No. 2, pp. 253-256 (2002).
Parathath et al. Nitrix oxide synthase isoforms undertake unique roles during excitoxicity. Stroke, vol. 38, pp. 1938-1945 (2007).
Sakanaka et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Abstract; Proc. Natl. Acad. Sci. USA vol. 95, pp. 4635-4640 (Apr. 1998).
Siren et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Abstract; Proc. Natl. Acad. Sci. USA vol. 98/7, pp. 4044-4049 (Mar. 2001).
Morishita et al. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Abstract; Neuroscience vol. 76/1 pp. 105-116 (1997).
Heck et al. Insulin-like growth factor-1-mediated neuroprotection against oxidative stress is associated with activation of nuclear kappaB. Abstract; J. Biol. Chem. vol. 274/14 pp. 9828-9835 (Apr. 1999).
Sizonenko et al. Neuroprotective effects of the N-terminal tripeptide of IGF-1, glycine-proline-glutamate, in the immature rat brain after hypoxic-ischemic injury. Abstract; Brain Res. vol. 922/1 pp. 42-50 (Dec. 2001).
Liu et al. Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. Abstract; J. Neurol. Sci. vol. 187/1-2 pp. 91-97 (Jun. 2001).
Tagami et al. Insulin-like growth factors prevent apoptosis in cortical neurons isolated from stroke-prone spontaneously hypertensive rats. Abstract; Lab Invest. vol. 76/5 pp. 603-612 (May 1997).
Digicaylioglu et al. Erythropoietin protects rat central neurons from NMDA- and NO-induced apoptosis. Society for Neuroscience Abstracts, 1997, vol. 23, No. 1-2, pp. 1667. Meeting Info:27th Annual Meeting of the Society for Neuroscience, New Orleans, Louisiana, USA (Oct. 25-30, 1997).
Tagami et al. Insulin-like growth factors prevent apoptosis in cortical neurons isolated from stroke-prone spontaneously hypertensive rats. Laboratory Investigation, vol. 76, No. 5, pp. 603-612 (1997).
Arsenijevic and Weiss, “Insulin-like growth factor-I is a differentiation factor for postmitotic CNS stem cell-derived neuronal precursors: distinct actions from those of brain-derived neurotrophic factor,”J. Neurosci. 18:2118-2128 (1998).
Bain et al., “Embryonic stem cells express neuronal properties in vitro,”Devel. Biol. 168:342-357 (1995).
Barbone et al., “New epoetin molecules and novel therapeutic approaches,”Nephrol. Dial. Transplant14 (Suppl. 2) :80-84 (1999).
Bayne et al., “The roles of tyrosines 24, 31, and 60 in the high affinity binding of insulin-like growth factor-I to the type 1 insulin-like growth factor receptor,”J. Biol. Chem. 265:15648-15652 (1990).
Bhatia et al., “A newly discovered class of human hematopoietic cells with SCID-repopulating activity,”Nature Medicine4:1038-1045 (1998).
Brines et al., “Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury,”Proc. Natl. Acad. Sci. USA97:10526-10531 (2000).
Brooker et al., “Endogenous IGF-1 regulates the neuronal differentiation of adult stem cells,”J. Neurosci. Res. 59:332-341 (2000).
Cascieri and Bayne, “Analysis of the interaction of IGF-I analogs with the IGF-I receptor and IGF binding proteins,” in LeRoith and Raizada,Current Directions in Insulin-like Growth Factor Research, Plenum Press, New York, 1994.
Damen et al., “Phosphorylation of tyrosine 503 in the erythropoietin receptor (EpR) is essential for binding the P85 subunit of phosphatidylinositol (PI) 3-kinase and for EpR-associated PI 3-kinase activity,”J. Biol. Chem. 270:23402-23408 (1995).
Derby et al., “Identification of the residues involved in homodimer formation of recombinant human erythropoietin,”Int. J. Peptide Protein Res. 47:201-208 (1996).
DePaolis et al., “Characterization of erythropoietin dimerization,”J. Pharm. Sci. 84:1280-1284 (1995).
Digicaylioglu and Lipton, “Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades,”Nature412:641-647 (2001).
Digicaylioglu and Lipton, “Erythropoietin and IGF-1 Provide Neuroprotection from NMDA-Induced Apoptosis via a P13 Kinase/AKT Signaling Pathway,” Center for Neuroscience and Aging, The Burnham Institute, La Jolla, CA, USA, Session #764.16 (Aug. 2001).
Elliott et al., “Activation of the erythropoietin (EPO) receptor by bivalent anti-EPO receptor antibodies,”J. Biol. Chem. 271:24691-24697 (1996).
Francis et al., “Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency,”J. Mol. Endocrinol. 8:213-223 (1992).
Gary and Mattson, “Integrin signaling via the PI3-kinase-Akt pathway increases neuronal resistance to glutamate-induced apoptosis,”J. Neurochem. 76:1485-1496 (2001).
Ghosh and Greenberg, “Distinct roles for bFGF and NT-3 in the regulation of cortical neurogenesis,”Neuron15:89-103 (1995).
He et al., “Association of the p85 regulatory subunit of phosphatidylinositol 3-kinase with an essential erythropoietin receptor subdomain,”Bl
Digicaylioglu Murat
Lipton Stuart A.
Allen Marianne P
Brigham and Women's Hospital, Inc.
Burnham Institute for Medical Research
DeBerry Regina M
McDermott Will & Emery LLP
LandOfFree
Neuroprotective synergy of erythropoietin and insulin-like... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neuroprotective synergy of erythropoietin and insulin-like..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neuroprotective synergy of erythropoietin and insulin-like... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3994181